GE has announced five winners of its competition for the development of early breast cancer detection and diagnostic technologies—and two of the grants go to researchers studying triple-negative breast cancer. Yea! Check out GE’s interviews with the five winners and their research.
The two that focus on TNBC are:
• MyCancerGenome.org, a freely available online tool for doctors, patients, researchers and others that helps personalize the treatment of triple negative breast cancer by providing easily accessible, mutation-specific information and even clinical trials related to different forms of breast cancer.
• Researchers at Vanderbilt-Ingram Cancer Center, who have shown that gene expression analysis reveals at least six different subtypes for triple negative breast cancer, each of which is likely to respond differently to chemotherapy. The Center is now designing clinical trials with personalized therapy for each subtype.